- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05744310
장기 인공호흡이 ALS 환자와 그 가족의 삶의 질에 미치는 영향 (ALS-LTMV)
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years. The patient physical and psychological sufferings in ALS are immense, and apart from Riluzole, there is no effective treatment. Care of advanced ALS have an estimated cost of 4-8 million NOK per year. Perhaps the most challenging topic of ALS care is the decision to extend ventilation support into the stages of disease that require treatment both during day and night. In these cases, treatment is clearly life-sustaining and although quality of life may be maintained, the burden of caregiving imposed upon family or health care workers is huge, regardless of tracheostomy (TIV) or non-invasive (NIV) modality.
The present study is a longitudinal questionnaire study in Norway measuring overall quality of life, health-related quality of life, and disease-specific quality of life in ALS patients, partners and children before and after the introduction of life sustaining ventilation support. The investigators aim to increase the knowledge on how life-sustaining ventilation support with NIV or TIV affects the quality of life in ALS patients, life partners and children. The results from the study may provide crucial information for clinicians and patients on one of the most difficult ethical issues of ALS treatment. The investigators anticipate that this information will facilitate a shared decision making processes, weighing benefits and disadvantages in a wider perspective.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Ole-Bjørn Tysnes
- 전화번호: + 47 55975063
- 이메일: ole-bjorn.tysnes@helse-bergen.no
연구 연락처 백업
- 이름: Tale Litlere Bjerknes
- 전화번호: +47 55975045
- 이메일: tale.litlere.bjerknes@helse-bergen.no
연구 장소
-
-
-
Bergen, 노르웨이
- 모병
- Haukeland University Hospital
-
연락하다:
- Ole-Bjørn Tysnes
- 전화번호: +4755975063
- 이메일: ole-bjorn.tysnes@helse-bergen.no
-
Lørenskog, 노르웨이
- 모병
- Akershus University Hospital
-
수석 연구원:
- Ola Nakken
-
연락하다:
- Ola Nakken
-
Oslo, 노르웨이
- 모병
- Oslo University Hospital
-
수석 연구원:
- Angelina Maniaol
-
연락하다:
- Angelina Maniaol
-
Sarpsborg, 노르웨이, 1714
- 아직 모집하지 않음
- Østfold Hospital Kalnes
-
연락하다:
- Sophie Cranner Seip, MD
- 전화번호: +47 69 86 00 00
- 이메일: Sophie.Cranner.Seip@so-hf.no
-
Stavanger, 노르웨이
- 모병
- Stavanger University Hospital
-
수석 연구원:
- Katrin Ruth Schlüter
-
연락하다:
- Katrin Ruth Schlüter
-
Tromsø, 노르웨이
- 모병
- Universitetssykehuset Nord-Norge
-
연락하다:
- Agnethe Eltoft, MD
- 전화번호: +4777627075
- 이메일: agnethe.eltoft@unn.no
-
연락하다:
- Monica Vold, MD
- 이메일: monica.linnea.vold@unn.no
-
수석 연구원:
- Agnethe Eltoft, MD
-
수석 연구원:
- Monica Vold, MD
-
Trondheim, 노르웨이
- 모병
- St. Olavs Hospital
-
연락하다:
- Eivind Brønstad, MD PhD
-
수석 연구원:
- Eivind Brønstad, MD PhD
-
-
Nordland
-
Bodø, Nordland, 노르웨이, 8005
- 모병
- Nordland Hospital Bodø
-
연락하다:
- Ane Sjulstad, MD
- 전화번호: +47 75571000
- 이메일: Ane.Skaare.Sjulstad@nordlandssykehuset.no
-
-
Vest Agder
-
Kristiansand, Vest Agder, 노르웨이
- 모병
- Sørlandet Hospital Trust
-
연락하다:
- Hildegunn Øverlie, MD
- 전화번호: + 47 38073000
- 이메일: hildegunn.overlie@sshf.no
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria for patients:
- A clinical diagnosis of probable ALS according to the revised El Escorial criteria
- Progression of the illness leading the consulting physician to offer treatment with LTMV
- Can communicate in Norwegian
Inclusion criteria for partners of ALS patients:
- Partner of a patient with ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
- Can communicate in Norwegian
Inclusion criteria for children:
- Children from 8 years and older having a parent who suffers from ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
- Can communicate in Norwegian
Exclusion criteria for patients, partners and children of ALS patients:
1. Potential participants with cognitive impairment or dementia.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: LTMV 연명치료를 선택한 ALS 환자와 그 가족
|
Patients that choose life prolonging treatment with long term mechanical ventilation support |
|
활성 비교기: LTMV의 연명치료를 거부하는 ALS 환자와 그 가족
|
Patients that decline life prolonging treatment with long term mechanical ventilation support |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall quality of life assessed by the "Quality of Life Scale"
기간: At inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
At inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
기간: 3 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
3 months after inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
기간: 9 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
9 months after inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
기간: 15 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
15 months after inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
기간: 21 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
21 months after inclusion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Health-related quality of life assessed by the "EQ-5D-5L"
기간: At inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
At inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 3 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
3 months after inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 9 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
9 months after inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 15 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
15 months after inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 21 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
21 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: At inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
At inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 3 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
3 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 9 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
9 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 15 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
15 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 21 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
21 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: At inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
At inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 3 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
3 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 9 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
9 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 15 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
15 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 21 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
21 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
기간: At inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
At inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
기간: 3 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
3 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
기간: 9 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
9 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
기간: 15 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
15 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
기간: 21 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
21 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
기간: At inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
At inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
기간: 3 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
3 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
기간: 9 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
9 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
기간: 15 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
15 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
기간: 21 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
21 months after inclusion
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Ole-Bjørn Tysnes, Haukeland University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 492102
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .